Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PANDORE trial: what clinicians have said so far
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
- NCT03212651 ↗
- Completed
- Gustave Roussy, Cancer Campus, Grand Paris
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PANDORE (pembrolizumab in muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PANDORE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab
- Arms
- Patients with MIBC (Muscle Invasive Bladder Cancer) · Experimental
- Enrollment
- 41
- Primary outcomes
- Pathologic complete response rate
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris with Merck Sharp & Dohme LLC
- Start
- Oct 17, 2017
- Primary completion
- Jul 18, 2019
- Results posted
- No
- Registry record
- NCT03212651 · updated Jan 20, 2023